Iproclozide

Iproclozide
Clinical data
Routes of; administration	Oral
ATC code	N06AF06 (WHO) ;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 2-(4-chlorophenoxy)-N-isopropyl-acetohydrazide;
CAS Number	3544-35-2 ;
PubChem CID	19063;
ChemSpider	17998 ;
UNII	1II9D6CB3J;
KEGG	D07338 ;
ChEMBL	ChEMBL91238 ;
CompTox Dashboard (EPA)	DTXSID70188925 ;
ECHA InfoCard	100.020.536
Chemical and physical data
Formula	C11H15ClN2O2
Molar mass	242.70 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(OCC(=O)NNC(C)C)cc1;
	InChI InChI=1S/C11H15ClN2O2/c1-8(2)13-14-11(15)7-16-10-5-3-9(12)4-6-10/h3-6,8,13H,7H2,1-2H3,(H,14,15) ; Key:GGECDTUJZOXAAR-UHFFFAOYSA-N ;
(verify)

Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[1] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[2][3]

References

Suerinck A, Suerinck E (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.
Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. PMID 680506.
Neil Kaplowitz; Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid5930723-1] Suerinck A, Suerinck E (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.

[pmid680506-2] Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. PMID 680506.

[bookDrug-induced_liver_disease-3] Neil Kaplowitz; Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.

Anxiolytics (N05B)
5-HT_1AR agonists	Buspirone Gepirone^† Tandospirone
GABA_AR PAMs	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Chlormezanone^‡ Ethanol (alcohol) Etifoxine Imepitoin; Herbs: Kava Skullcap Valerian
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIs (e.g., escitalopram) SNRIs (e.g., duloxetine) SARIs (e.g., trazodone) TCAs (e.g., clomipramine^#) TeCAs (e.g., mirtazapine) MAOIs (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cannabidiol Cycloserine Fabomotizole Hydroxyzine Kanna Lavender Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Iproclozide

See also

References